Skip to main content

Search
For Media

Press Releases

|

NIH Awards $12 Million for Gene Therapy Work

Image Description

September 12, 2012

Seattle Children’s Research Institute, Fred Hutchinson Cancer Research Center, U Penn, UW, WSU push toward clinical trials for Severe Combined Immunodeficiency

Seattle Children’s Research Institute and partner organizations have been awarded more than $12 million over the next five years from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to develop foamy virus gene replacement therapy for patients who suffer from Severe Combined Immunodeficiency.  Researchers from Fred Hutchinson Cancer Research Center, University of Pennsylvania, University of Washington and Washington State University will collaborate with Seattle Children’s Research Institute and pursue various components of the therapy, with an aim of clinical trials for patients at the end of five years.  There has never been a clinical trial conducted using foamy viruses. 

A foamy virus is a type of retrovirus, which means it has the capability of allowing its genetic information to become part of the genetic information of a host cell.  The use of foamy viruses as a clinical vector for gene delivery was developed in Seattle. 

Severe Combined Immunodeficiency, or SCID, is a rare syndrome caused by mutations in at least 13 different genes. The most common form, SCID-X1, is the focus of the new study. SCID is now often called "bubble boy disease,” becoming more widely known during the 1970 and 1980s when the public learned about David Vetter, a boy with SCID who lived for 12 years in a plastic, germ-free environment.  The “bubble boy” story was featured in a made-for-TV movie starring John Travolta and on an episode of the popular television show, “Seinfeld.”

Patients with SCID have defective B- and T-cell function, which results in the onset of one or more serious infections within the first few months of life.  These infections—including pneumonia, meningitis and bloodstream sepsis—are life-threatening emergencies requiring complex medical care.  Treatment using marrow transplantation represents the only curative therapy for patients that survive initial infections.

“SCID is a rare condition and affects about one in 30,000 newborns,” said David Rawlings, MD, of Seattle Children’s Research Institute, co-leader of the project with Hans-Peter Kiem, MD, Fred Hutchinson Cancer Research Center.  “Among Hispanic newborn babies, that figure might be even higher, or one in 15,000.  Many children still die of infection before they are diagnosed,” said Dr. Rawlings, who is also chief of the Immunology Division at Seattle Children’s Hospital. 

Scientists in Seattle are actively developing several different facets of gene therapy, including gene replacement and gene repair for SCID and related diseases. 

“In the future, we hope that all SCID babies are diagnosed by newborn screening, and cured using foamy viral gene therapy before they suffer from an infection,” said Dr. Rawlings.  Newborn screening for SCID is now in place in 34 states and is under consideration in Washington state.

The experts aligned on this project are among the top in the field of gene therapy.  The senior leaders of the team include:
•  David Rawlings MD, Andrew Scharenberg, MD, and Troy Torgerson, MD, PhD, Seattle Children’s Research Institute (modeling preclinical therapies and immune function studies)
•  Hans-Peter Kiem, MD,  Brian Beard, PhD,  and Ralf Luche, PhD, Fred Hutchinson Cancer Research Center (modeling preclinical therapies, producing virus and tracking vector integration)
•  Peter Felsburg, VMD, PhD, University of Pennsylvania (modeling preclinical therapies)
•  Grant Trobridge, PhD, Washington State University (optimizing vector safety and tracking vector integration)
•  Scott Wilbur, PhD, University of Washington (modeling preclinical therapies)

The majority of the $12 million award will remain in Washington state, and will help boost the state’s economy.  This comes at a time of dwindling federal grants and a much more competitive process from the National Institutes of Health.  Several laboratory positions at Seattle Children’s Research Institute will be preserved, thanks to the award.

The research project is supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number P01AI097100.

Seattle Children’s Research Institute, Fred Hutchinson Cancer Research Center, U Penn, UW, WSU push toward clinical trials for Severe Combined Immunodeficiency
 

About Seattle Children’s Research Institute

Located in downtown Seattle’s biotech corridor, Seattle Children’s Research Institute is pushing the boundaries of medical research to find cures for pediatric diseases and improve outcomes for children all over the world. Internationally recognized investigators and staff at the research institute are advancing new discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics, among others. As part of Seattle Children’s Hospital, the research institute brings together leading minds in pediatric research to provide patients with the best care possible. Seattle Children’s serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. For more information, visit http://www.seattlechildrens.org/research.

Latest News

Vaccine Safety: Getting the Message to Parents in Doubt
8.28.14 — U.S. News & World Report

Measles, mumps and whooping cough have been around a long time – along with the vaccines to prevent them. But instead of being ... cont.

Depressed Teens May Need Extra Support To Stick With Treatment
8.27.14 — NPR

A new study from Seattle Children’s Research Institute suggests integrating mental health treatment into primary care may ... cont.

Can running cure depression? Seattle Children’s brain research finds exercise can help patients
8.26.14 — Puget Sound Business Journal

Researchers at Seattle Children’s Research Institute have pinpointed a tiny area of the brain that controls our motivation to ... cont.